Amedisys (AMED) Stock Price, News & Analysis

Company Overview

Amedisys, Inc. is a leading provider of home health, hospice and personal care services in the United States. Through its network of local care centers, the company delivers skilled nursing, physical and occupational therapies, medical social work, home health aides and related clinical support to patients in their homes. Its hospice division offers comprehensive end-of-life care, including pain management, counseling and bereavement support, designed to meet the physical, emotional and spiritual needs of terminally ill patients and their families.

The company operates under three primary service lines. Its home health segment focuses on post-acute care and chronic disease management, leveraging interdisciplinary teams to support recovery and independence. The hospice segment provides individualized care plans and around-the-clock clinical oversight, aiming to maintain patient comfort and dignity. Amedisys also offers personal care services, which include non-medical assistance with daily living activities such as bathing, dressing and meal preparation, to help clients remain safely in their homes.

Headquartered in Baton Rouge, Louisiana, Amedisys serves communities across more than 30 states and the District of Columbia. The company’s geographically diverse footprint allows it to tailor care solutions to urban, suburban and rural populations alike, often collaborating with hospitals, physician groups and payers to enhance care transitions and reduce avoidable hospital readmissions. Amedisys has pursued strategic growth through the development of new care centers and selective acquisitions aimed at expanding its service offerings and market reach.

Founded in 1982, Amedisys has grown from a regional home health provider into one of the nation’s largest post-acute care companies. The organization is led by President and Chief Executive Officer Paul F. Kusserow, who has overseen initiatives to integrate digital health tools, streamline clinical workflows and strengthen patient engagement. Under his leadership, the company has continued to focus on improving quality outcomes, enhancing caregiver support and driving operational efficiencies.

Key Stats

• Today's Range: $100.93 to $101.02
• 50-Day Range: $96.91 to $101.01
• 52-Week Range: $82.15 to $101.02
• Volume: 1.06 million shs
• Average Volume: 780,222 shs
• Market Capitalization: $3.32 billion
• P/E Ratio: 39.30
• Dividend Yield: N/A
• Price Target: $100.50
• Consensus Rating: Moderate Buy

Amedisys Stock Analysis - MarketRank™

Amedisys scored higher than 41% of companies evaluated by MarketBeat, and ranked 707th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Amedisys has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for Amedisys is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Amedisys has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 10.00%

Earnings Growth

Earnings for Amedisys are expected to grow by 10.00% in the coming year, from $4.40 to $4.84 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Amedisys is 39.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 279.81.

Price to Earnings Ratio vs. Sector

The P/E ratio of Amedisys is 39.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.54.

Price to Earnings Growth Ratio

Amedisys has a PEG Ratio of 1.34. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Amedisys has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AMED.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Amedisys does not currently pay a dividend.

Dividend Growth

Amedisys does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 5.0 / 5
• Environmental Score: -0.61

Short Interest

There is no current short interest data available for AMED.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: N/A

News Sentiment

Amedisys has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

MarketBeat Follows

1 people have added Amedisys to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Amedisys insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.10% of the stock of Amedisys is held by insiders.

Percentage Held by Institutions

94.36% of the stock of Amedisys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AMED Stock Analysis - Frequently Asked Questions

How were Amedisys' earnings last quarter?

Amedisys, Inc. (NASDAQ:AMED) released its earnings results on Tuesday, July, 29th. The health services provider reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.39 by $0.15. The firm's revenue was up 5.2% on a year-over-year basis.

Who are Amedisys' major shareholders?

Amedisys' top institutional shareholders include Alpine Associates Management Inc. (3.34%), State Street Corp (3.25%), Norges Bank (2.74%) and Qube Research & Technologies Ltd (2.40%).
View institutional ownership trends.

What other stocks do shareholders of Amedisys own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Amedisys investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

• Last Earnings: 7/29/2025
• Today: 9/19/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - OUTP/HM CRE
• Sub-Industry: Health Care Services
• Current Symbol: NASDAQ:AMED
• CIK: 896262
• Web: www.amedisys.com
• Phone: (225) 292-2031
• Fax: 225-292-8163
• Employees: 20,000
• Year Founded: 1982

Price Target and Rating

• Average Price Target for Amedisys: $100.50
• High Price Target: $101.00
• Low Price Target: $100.00
• Potential Upside/Downside: -0.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.57
• Trailing P/E Ratio: 39.30
• Forward P/E Ratio: 22.96
• P/E Growth: 1.34
• Net Income: $43.23 million
• Net Margins: 3.56%
• Pretax Margin: 6.21%
• Return on Equity: 12.91%
• Return on Assets: 7.29%

Debt

• Debt-to-Equity Ratio: 0.26
• Current Ratio: 1.36
• Quick Ratio: 1.36

Sales & Book Value

• Annual Sales: $2.40 billion
• Price / Sales: 1.38
• Cash Flow: $6.24 per share
• Price / Cash Flow: 16.20
• Book Value: $38.77 per share
• Price / Book: 2.61

Miscellaneous

• Outstanding Shares: 32,887,000
• Free Float: 32,196,000
• Market Cap: $3.32 billion
• Optionable: Optionable
• Beta: 0.89